Advisory Committee

Lori Brisbin is a molecular biologist who leads Texas Oncology’s Precision Medicine program. She is responsible for maximizing the use of precision medicine within Texas Oncology, focusing on data capture and utilization for research, as well as collaboration with pharmaceutical partners for clinical trials matching and data aggregation.

Ms. Brisbin previously served as chief commercial officer for Medfusion, where she led an expansion of the molecular oncology program and helped implement genetic test data capture capabilities for Texas Oncology and Rocky Mountain Cancer Centers. She previously worked at Roche Molecular Systems, QIAGEN, and Novartis, where she helped develop molecular genetic solutions for oncology and infectious disease.

Lori Brisbin earned a Master of Science degree in molecular biology from Syracuse University in Syracuse, New York.

Dr. Hwang is a molecular and solid tumor pathologist at PhenoPath/Quest Laboratories in Seattle, Washington.   Dr. Hwang joined PhenoPath in 2008 and began overseeing the Molecular Pathology department and participating in the clinical and contract research immunohistochemistry services. 

He received his MD from the University of Pennsylvania and his Pathology residency training (AP/CP) at the University of Washington. Dr. Hwang completed a diagnostic immunohistochemistry pathology fellowship with Dr. Allen Gown at PhenoPath and was also a postdoctoral research fellow at the Fred Hutchinson Cancer Research Center, working in the areas of cancer and the cell cycle.

Goetz Kloecker, MD, MBA, MSPH, FACP, graduated from medical school in Munich, Germany. He did internal medicine residencies at the University of Nuremberg/Erlangen, the Free University of Berlin, and the University of Louisville, KY. At the University of Louisville, Dr. Kloecker served as a tenured full professor of medicine, the hematology/oncology fellowship director, and the director of the Thoracic Oncology Clinic for more than 10 years. Since 2020, he has been a gratis faculty member at the University of Louisville.

Dr. Kloecker has authored more than 60 peer-reviewed articles, and recently the book, Lung Cancer: Standards of Care. He has received multiple grants and awards, among them Kentucky Colonel, Distinguished Clinical Faculty, and Top Doc Louisville. Dr. Kloecker now is the co-director of thoracic oncology at St Elizabeth Healthcare in Edgewood, KY. He is engaged in multidisciplinary clinical care and clinical trials for patients with lung cancer. Dr. Kloecker is also interested in medical education and hopes to improve the outcomes of thoracic malignancies in the Commonwealth of Kentucky.

Amy Jo Pixley, MSN, RN, OCN, ONN-CG(T), has been a nurse for over 30 years and currently is an oncology nurse navigator in thoracic and melanoma at the Ann B. Barshinger Cancer Institute, Penn Medicine Lancaster General Health in Lancaster, Pennsylvania.  She has experience in pediatrics, adult and pediatric critical care and trauma, nursing administration, case management, and pediatric and adult oncology. She has served as adjunct faculty to the Lancaster General College and Health Sciences. 

Ms. Pixley speaks nationally on topics in thoracic oncology and other cancer-related topics for community and support groups such as awareness lectures and intimacy after treatment. She has presented educational sessions on establishing Nurse Navigation programs to organizations such as the Pennsylvania Cancer Control Consortium. She has published articles for patients and caregivers in Conquer Magazine related to immunotherapy and shared decision making, and co-authored articles for the Journal of Oncology Navigation and Survivorship.

She is currently a certified oncology nurse, certified nurse navigator generalist and thoracic specialty, and a member of both the Oncology Nursing Society and the Academy of Oncology Nurse and Patient Navigators.  Ms. Pixley received her undergraduate degree from Bloomsburg University and a Master of Science in Nursing from Walden University. 

Dr. Sinchita Roy-Chowdhuri is an associate professor at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas, where she specializes in cytopathology and molecular pathology.  She is currently the medical director of the Molecular Diagnostic Laboratory Solid Tumor section and the Director of Molecular Cytopathology at MDACC, and she serves as the principal investigator for the NCI-MATCH adult and pediatric clinical trials. Her research interests include lung cancer biomarkers, molecular diagnostics in solid tumors, and the application of ancillary studies in cytopathology.

Dr. Roy-Chowdhuri has presented several educational courses at national and international meetings, and she has published more than 100 peer-reviewed articles in the field of cytopathology and molecular pathology. She has authored several book chapters and is co-editor of the book, Molecular Diagnostics in Cytopathology: A Practical handbook for the Practicing Pathologist. She serves as the associate editor for Cancer Cytopathology and the Archives of Pathology and Laboratory Medicine. She is a committee member in several professional societies, serves as a mentor to pathology trainees, and co-founded a pathology educational mobile app, CytoAtlas.

Krysten Shipley is a board-certified genetic counselor with experience in both inherited and tumor genomic testing. Ms. Shipley currently works as a clinical oncology specialist at Guardant Health, where she specializes in providing education to healthcare professionals in the use and interpretation of genomic testing. Prior to working at Guardant Health, Ms. Shipley was a genetic counselor at the University of Iowa Holden Comprehensive Cancer Center, where she focused on providing genetic counseling for inherited cancer conditions.

Ms. Shipley received her master’s degree in Medical & Molecular Genetics from Indiana University and her bachelor’s degree in Biochemistry & Psychology from the University of Northern Iowa.

Dr. Silvestri is the George Sr. and Margaret Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina.  He is widely regarded as an international expert in lung cancer and procedures related to management of the disease. His research includes screening for lung cancer, lung nodule evaluation, diagnosis and staging of lung cancer, and technology assessment.

Dr. Silvestri is a writer and editor of the American College of Chest Physicians lung cancer guidelines.  He is a past president of the American Association of Bronchology and Interventional Pulmonology. Dr. Silvestri has authored more than 200 scientific articles, book chapters, and editorials. He has served on multiple editorial boards of medical journals and currently serves on the editorial board of the journal Chest. Dr. Silvestri was the president of the American College of Chest Physicians in 2017. He currently serves on the steering committee of the National Lung Cancer Roundtable.

Dr. Silvestri completed his training in Pulmonary and Critical Care at Dartmouth.  He has an advanced degree in the evaluative clinical sciences, also from Dartmouth.

Dr. Alex Spira is director of the Virginia Cancer Specialists (VCS) Research Institute and the Phase I Trial Program, where he is actively involved in advancing medicine and offering targeted treatment options for patients. He also is co-chair of the US Oncology Thoracic Oncology Committee, chair of the US Oncology Research Executive Committee, and a member of the US Oncology National Policy Board Executive Committee. Dr. Spira is a faculty member at The Johns Hopkins University School of Medicine, where he is assistant professor of oncology. His research interests include immunotherapy, personalized medicine, gastrointestinal, thoracic, and lung cancer and sarcomas.

Throughout his career, Dr. Spira has been recognized as a Top Doctor in Northern Virginia Magazine and Washingtonian magazine for multiple years. In 2014, he received the prestigious Castle Connolly America’s Top Doctor award.

Dr. Spira earned his medical degree from the New York University School of Medicine. He completed his internship and residency at the Hospital of the University of Pennsylvania and his medical oncology fellowship at The Johns Hopkins Hospital.  He has been honored with the National Institutes of Health Medical Scientist Training Program Fellowship (1990-1997), Merck Corporation Scholarship (1995-1995), Pediatric AIDS Foundation Fellowship (1993- 1995), and Harvard University Scholarship (1987-1990). He received his PhD from the New York School of Arts and Sciences.

David M. Waterhouse, MD, MPH, is a medical oncologist and hematologist with Oncology Hematology Care (OHC) in Cincinnati, Ohio. Dr. Waterhouse’s specialties are lunch cancer and urologic cancer. He is the founder and co-director of OHC’s nationally recognized Clinical Research Program and a former strategic partner in the Sarah Cannon Research Network. He is currently a national network principal investigator for The US Oncology Network and US Oncology Research and is a member of its Research Executive Committee and an associate director of the Lung Cancer Committee. He is also active within US Oncology’s HOER program.

Dr. Waterhouse is the recipient of numerous recognitions, including the US Oncology’s inaugural Culture of Research Award (2020), Oncology Time’s Excellence in Oncology Award (2019), The US Oncology Network’s Excellence in Clinical Research Award (2017), Cancer Support Community Inspiration in Cancer Award (2016), Cincinnati Health Care Hero (Innovation) award (2016) and is a two-time winner of ASCO’s Clinical Trials Participation Award (2015, 2007). Dr. Waterhouse is a former ASCO Young Investigator and past-chair of the ASCO Research Community Forum. He is also a former member of ASCO’s Cancer Research Committee.

Dr. Waterhouse received his medical degree from the University of Massachusetts. He completed a fellowship in medical oncology and hematology at the University of Michigan in Ann Arbor, where he also earned a master’s degree in public health.